Breast cancer, version 1.2016 featured updates to the NCCN guidelines

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. PierceElizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dottie A. Shead, Rashmi Kumar

Research output: Contribution to journalArticlepeer-review

136 Scopus citations

Abstract

These NCCN Guideline Insights highlight the important updates to the systemic therapy recommendations in the 2016 NCCN Guidelines for Breast Cancer. In the most recent version of these guidelines, the NCCN Breast Cancer Panel included a new section on the principles of preoperative systemic therapy. In addition, based on new evidence, the panel updated systemic therapy recommendations for women with hormone receptor-positive breast cancer in the adjuvant and metastatic disease settings and for patients with HER2-positive metastatic breast cancer. This report summarizes these recent updates and discusses the rationale behind them.

Original languageEnglish
Pages (from-to)1475-1485
Number of pages11
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume13
Issue number12
DOIs
StatePublished - Dec 1 2015

Keywords

  • Breast Neoplasms/therapy
  • Female
  • Humans

Fingerprint

Dive into the research topics of 'Breast cancer, version 1.2016 featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this